Extended Access of Momelotinib in Adults With Myelofibrosis

Cancer research · Myelofibrosis

Extended access is designed to evaluate the long‑term safety and efficacy of momelotinib in adults with myelofibrosis by continuing treatment and monitoring overall survival and leukemia‑free survival.

This Phase 2 study is an extended‑access program for adults with myelofibrosis who are already taking momelotinib in other studies. It aims to monitor the long‑term safety of momelotinib, as well as its impact on overall survival and the prevention of progression to leukemia.

Ensures patients who benefit from momelotinib can continue treatment while providing data on long‑term safety and effectiveness, which is crucial for clinical decision‑making.

Evidence level: Állatkísérletes. Állatmodellben vizsgálták.

Original source

Related signals